Eye Inflammation Treatment Market, by Drug Class (Monoclonal Antibodies, Antibiotics, Corticosteroids, Antivirals, Antifungal, Others (Analgesics, etc.)), by Dosage Form (Eye Drops, Tablets, Capsules, Others (Ophthalmic Ointments, etc.)), by Distribution

Eye Inflammation Treatment Market, by Drug Class (Monoclonal Antibodies, Antibiotics, Corticosteroids, Antivirals, Antifungal, Others (Analgesics, etc.)), by Dosage Form (Eye Drops, Tablets, Capsules, Others (Ophthalmic Ointments, etc.)), by Distribution Channels, (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Eye inflammation, also known as ocular inflammation, is a disorder marked by the swelling of one or more eye regions and can be brought on by a number of different things, from minor irritation to specific illnesses. Eye Inflammation is classified according to the part of the eye that has been affected. Scleritis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, and Panuveitis are the different classifications. Panuveitis is a general word for an inflammation that affects the entire eye.

Eye inflammation is caused by various factors such as inflammatory diseases, injuries in the eye, microbial infections such as viral, bacterial, and fungal infection or exposure to certain toxic chemicals such as strong acids or pesticides.

Market Dynamics

Increasing prevalence of autoimmune disorders is also expected to benefit in growth of the global eye inflammation treatment market, over the forecast period. For instance, according to a study published in February 2019 by National Multiple Sclerosis Society, in the journal Neurology, in 2017, nearly 1 million adults were living with multiple sclerosis in the U.S. Multiple sclerosis is a disease that reasons inflammation and damage to the optic nerve that cases optic neuritis. Optic neuritis as an early sign of multiple sclerosis. Optic neuritis causes pain in eye, vision loss in one eye, etc. Steroid are used as a medication to reduce inflammation in the optic nerve, which is expected to drive the global eye inflammation market.

Moreover, advanced treatment of eye disease is expected to propel the growth of global eye inflammation treatment market, over the forecast period. For instance, according to data published on November 04, 2021, by American Academy of Ophthalmology, new dry eye treatments may be more effective than existing ones. Modern treatments for eye disease include lifestyle changes, a nasal spray, punctual plugs, anti-inflammatory medications, deep-cleaning devices, and specialized contact lenses. Currently available medications for the treatment of dry eye disease, approved by the U.S. Food and Drug Administration are Tyrvaya, Restasis, Cequa, Xiidra and Eysuvis.

Key features of the study:

• This report provides an in-depth analysis of the global eye inflammation treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global eye inflammation treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include GSK plc., Alcon Laboratories Inc., Merck & Co. Inc., Alimera Sciences, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Akron Pharma Inc., Intas Pharmaceuticals Ltd., Amgen Inc., Sanofi S.A., Johnson & Johnson Services Inc., Pfizer Inc., Macleods Pharmaceuticals Ltd., Mylan N.V., Bausch Health Companies Inc.
• Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global eye inflammation treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global eye inflammation treatment market

Detailed Segmentation:

• Global Eye Inflammation Treatment Market, By Drug Class:
• Monoclonal Antibodies
• Antibiotics
• Corticosteroids
• Antivirals
• Antifungal
• Others (Analgesics, etc.)
• Global Eye Inflammation Treatment Market, By Dosage Form:
• Eye Drops
• Tablets
• Capsules
• Others (Ophthalmic Ointments, etc.)
• Global Eye Inflammation Treatment Market, By Distribution Channels:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Eye Inflammation Treatment Market, By Region:
• North America

By Country:

• U.S.
• Canada
• Latin America

By Country:

• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe

By Country:

• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• Asia Pacific

By Country:

• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• Middle East

By Country:

• GCC
• Israel
• Rest of Middle East
• Africa

By Country/Region:

• South Africa
• Central Africa
• North Africa
• Company Profiles
• Novartis AG *

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

• Alcon Laboratories Inc.
• Merck & Co. Inc.
• Alimera Sciences, Inc.,
• AbbVie Inc
• Teva Pharmaceutical Industries Ltd.
• Akron Pharma Inc
• Intas Pharmaceuticals Ltd
• Amgen Inc.
• Sanofi S.A.
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Macleods Pharmaceuticals Ltd.
• Mylan N.V.
• Bausch Health Companies Inc.

“*” marked represents similar segmentation in other categories in the respective section.